SynVivo is a leader in human-relevant organ-on-a-chip technology, providing advanced 3D in vitro models that replicate the native tissue microenvironment for drug discovery, toxicology, and translational research. Our cell-based microfluidic platforms integrate the precision of bioengineering and microvascular flow to deliver predictive, real-time data on cellular behavior, drug delivery, and therapeutic response.

SynVivo’s proprietary organ-on-a-chip platforms—including SynBBB™ (blood-brain barrier chip), SynTumor™ (cancer-on-a-chip), SynALI™ (lung-on-a-chip), SynRAM™ (inflammation-on-a-chip), and SynTox™ (toxicology-on-a-chip)—bridge the gap between traditional preclinical models and human biology. Each platform enables dynamic flow and shear stress, supporting a microvascular network that mimics natural circulation for more accurate modeling of BBB transcytosis, tumor microenvironments, respiratory infection, immunotoxicology, and systemic toxicology.

Cells cultured in SynVivo chips retain physiological function and gene expression patterns comparable to those found in vivo, producing human-relevant data aligned with New Approach Methodologies (NAMs) and the FDA Modernization Act. Published studies consistently show that SynVivo’s microvascular networks outperform static 2D culture systems, providing greater fidelity for barrier function, drug permeability, and inflammatory responses.

By enabling the use of patient-derived cells to recreate complex tissue and tumor microenvironments, SynVivo organ-on-chip models support a personalized medicine approach—allowing researchers to evaluate drug efficacy, safety, and combination strategies with unprecedented precision.